Methods for preparing functionalized fibers

By using atmospheric plasma treatment with vinyl monomers and proteins with free thiol groups, the method enhances porosity and binding capacity of nanowebs, addressing inefficiencies in existing fiber functionalization for chromatography.

JP2024543596AInactive Publication Date: 2024-11-21DDP SPECIALTY ELECTRONICS MATERIALS US LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024533049
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-02
Filing Date
2022-12-02
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for producing functionalized fibers for chromatography applications, particularly for biologics like monoclonal antibodies, are inefficient in achieving optimal porosity and binding capacity due to limitations in surface functionalization and protein attachment processes.

Method used

A method involving atmospheric plasma treatment of nanowebs with vinyl monomers and proteins capable of forming covalent bonds, specifically using dielectric barrier discharge plasma to coat nanowebs with proteins containing free thiol groups, enhancing porosity and binding capacity.

Benefits of technology

The method results in nanowebs with improved porosity and enhanced protein binding capacity, facilitating efficient affinity capture and elution processes for biologics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543596000001
    Figure 2024543596000001
  • Figure 2024543596000002
    Figure 2024543596000002
  • Figure 2024543596000003
    Figure 2024543596000003
Patent Text Reader

Abstract

A method is described for functionalizing a nanoweb having an average through-pore size of 0.1-5 μm and a porosity of 40-90% by volume to produce a functionalized nanoweb. The method includes exposing the nanoweb to a vinyl monomer in an atmospheric pressure plasma and then to a molecule capable of binding other molecules to the active sites.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates generally to methods for producing functionalized nanowebs useful in chromatography. [Background technology]

[0002] During the production of biopharmaceuticals, particularly antibody-derived therapeutics, such as monoclonal antibodies, an affinity capture and elution purification step is frequently used. This step most typically involves the binding of the desired therapeutic agent by a protein ligand conjugated to a chromatographic support. Some support materials require surface functionalization before the protein ligand is attached to the functionalized support surface. Fibers are used as support materials, for example as shown in Z. Ma et al., J. Chromatogr. B, 877 (2009) 3686-3694, where the fibers are exposed to air plasma and then immersed in a liquid phase of methacrylic acid to react and produce functionalized fibers. In another step, in a liquid phase reaction, proteins are attached to functionalized fibers via amino groups on the proteins. Summary of the Invention [Means for solving the problem]

[0003] The present invention relates to a method for functionalizing a nanoweb having an average through-pore size of 0.1 to 5 μm and a porosity of 40 to 90% by volume to produce a functionalized nanoweb, the method comprising: a) exposing the nanoweb and a vinyl monomer to an atmospheric plasma to produce a coated nanoweb; b) exposing the coated nanoweb and an aerosol containing molecules capable of forming covalent bonds, preferably proteins, to atmospheric plasma.

[0004] The present invention further relates to a method for functionalizing a nanoweb having an average through-pore size of 0.1 to 5 μm and a porosity of 40 to 90% by volume to produce a functionalized nanoweb comprising a protein, the method comprising: a) exposing the nanoweb and a vinyl monomer to an atmospheric plasma to produce a coated nanoweb; b) exposing the coated nanoweb to a protein that (i) is capable of binding other proteins to active sites and (ii) contains free thiol groups; The method includes: DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0005] Unless otherwise stated, all percentages are weight percentages (wt%) and all temperatures are in °C. Averages are arithmetic means unless otherwise stated. All operations are performed at room temperature (18-25 °C) unless otherwise specified. The terms "(meth)acrylate", "(meth)acrylic", and "(meth)acrylamide" refer to acrylate or methacrylate, acrylic or methacrylic, and acrylamide or methacrylamide, respectively (collectively, "acrylic monomers"). An acrylic polymer is a polymer that contains at least 50% by weight polymerized units of (meth)acrylic acid, alkyl, glycidyl or hydroxyalkyl (meth)acrylate, alkyl, glycidyl and / or hydroxyalkyl (meth)acrylamide, or combinations thereof. A carbohydrate polymer is a polymer that contains polymerized units of sugar molecules, i.e., polysaccharides, and polysaccharides functionalized via ether or ester groups are considered to be within this definition.

[0006] A web of randomly distributed fibers is generally called a "nonwoven." The fibers may or may not be bonded to each other, preferably they are not bonded. A "nanoweb" is a nonwoven web comprising at least one nanofiber. A nanoweb may also be called a "nanofiber mat." Preferably, the fibers in a nanoweb are "continuous," i.e., laid down in one continuous stream to form the web. The fiber diameter can be determined by SEM photo inspection. Preferably, the fibers have a diameter of 0.1-1 μm. Preferably, at least 95% of the fibers have a diameter in the stated range, based on the length of the fiber. Preferably, if less than 95% of the fibers have a diameter in the stated range, the fiber diameter is the arithmetic average of at least 50 measurements, preferably at least 100 measurements.

[0007] Preferably, the nanoweb has an average through-pore size of at least 0.15 μm, preferably at least 0.2 μm, preferably at least 0.25 μm, preferably 2 μm or less, preferably 1 μm or less, preferably 0.5 μm or less. The average through-pore size is a quantity calculated from material porometry measurements, where a dry sample is subjected to airflow at various flow rates, then wetted with a fluid of known surface tension, and the airflow is returned at a steadily increasing flow rate until the last wetted pores of the material are evacuated with air. The average through-pore size is determined from the 1 / 2 slope of the dry airflow curve intersecting the wetting flow curve. The relationship between fiber size and average through-pore size has been determined. Simmonds et al. found that the average fiber size D of a nonwoven fabric is 0.01 μm. fiber From the above, the average through-pore diameter D mean,pore To determine this, the following relationship was proposed (see Simmonds GE, Bomberger JD, Bryner MA. Designing nonwovens to meet pore size specifications. J Eng Fibers Fabrics. 2007;2 (1), 1-15): D mean,pore =0.39267*D fiber / (1-porosity)

[0008] Preferably, the nanoweb has a porosity of 40-90% by volume, preferably at least 50% by volume, preferably at least 60% by volume, preferably no more than 85% by volume, preferably no more than 80% by volume, preferably no more than 75% by volume. Fluid flow through the nanofiber mat is facilitated by high porosity, and smaller pore sizes are believed to improve substrate binding capacity. Preferably, when the pore size is 0.1-1 microns, the porosity is 50-90% by volume. Preferably, when the pore size is 0.1-0.5 microns, the porosity is 65 to 85% by volume, the porosity being calculated from the following formula: Porosity = 1 - (mass of fiber (g / cm 2 )) / (nanofiber mat thickness (cm) × polymer density (g / cm 3 ))

[0009] Preferably, the fibers comprise a synthetic polymer, preferably poly(vinylidene fluoride) (PVDF), a copolymer of PVDF such as poly(vinylidene fluoride-co-trifluoroethylene), a polyamide, polyethersulfone (PES), polyethylene, polypropylene, polyester, polyimide, or a combination thereof, preferably the fibers comprise PVDF, polyethersulfone, nylon, or a combination thereof. Preferably, the PVDF polymer has a number average molecular weight of 100,000 to 2,000,000, preferably 200,000 to 500,000 Daltons. Preferably, the polyamide has a number average molecular weight of 5,000 to 40,000, preferably 10,000 to 20,000. Preferably, the polyethersulfone has a number average molecular weight of 20,000 to 80,000, preferably 40,000 to 60,000. In a preferred embodiment of the invention the fibres comprise PVDF, preferably the fibres comprise at least 50% by weight PVDF, preferably at least 80% by weight, preferably at least 90% by weight, preferably at least 95% by weight PVDF.

[0010] Preferably, the vinyl monomer comprises at least one epoxy group, preferably 1 to 4, preferably 1 to 2, preferably 1. Preferably, the vinyl monomer comprises an ester or ether of (i) an epoxy alcohol, or (ii) an acetylenic alcohol. Preferably, the vinyl monomer is an ether of an epoxy alcohol, preferably glycidyl alcohol (e.g., vinyl glycidyl ether). Preferably, the vinyl monomer is an ester of an epoxy alcohol. Preferably, the ester is a (meth)acrylate ester. Preferably, the epoxy alcohol is glycidyl alcohol. Preferably, the vinyl monomer is a (meth)acrylate ester of glycidyl alcohol, preferably glycidyl (meth)acrylate.

[0011] In a preferred embodiment, the nanoweb is exposed in plasma to a vinyl monomer containing at least one hydrophilic group prior to the introduction of the vinyl monomer containing at least one epoxy group. Preferably, the hydrophilic group is hydroxyl, carboxylic acid, polyethylene glycol, methoxypolyethylene glycol, preferably hydroxyl. Preferably, the vinyl monomer is a (meth)acrylate ester, PEG (meth)acrylate, (meth)acrylamide, or (meth)acrylic acid, with a hydrophilic group on the ester alkyl group, preferably a hydroxyalkyl (meth)acrylate, preferably 2-hydroxyethyl methacrylate (HEMA), 2-hydroxyethyl acrylate (HEA), 2-hydroxypropyl methacrylate, 2-hydroxypropyl acrylate, 4-hydroxybutyl methacrylate, 4-hydroxybutyl acrylate, or mixtures thereof, preferably HEMA, or HEA. In another preferred embodiment, the vinyl monomer containing at least one hydrophilic group is contacted with the vinyl monomer and the nanoweb simultaneously.

[0012] Molecules capable of forming covalent bonds may include, but are not limited to, molecules that contain nucleophilic groups. These nucleophilic groups may include, but are not limited to, hydroxyl, amine, or thiol groups. These groups may be found in amino acids, peptides, proteins, nucleic acids, polynucleic acids, viruses, and cells, among others. Preferably, the molecules capable of forming covalent bonds are proteins.

[0013] In one preferred embodiment of the invention, the fiber, the vinyl monomer, and the protein are simultaneously present in the plasma environment. In another preferred embodiment of the invention, the fiber is first functionalized with the vinyl monomer in the plasma, and then the functionalized fiber is contacted with the protein in the plasma. In another preferred embodiment, the fiber is first functionalized with the vinyl monomer in the plasma, and then the functionalized fiber is contacted with the protein in an aqueous medium.

[0014] Preferably, the protein comprises a free cysteine ​​thiol group, i.e. a thiol group (-SH) that is not part of a disulfide bond, and said protein is active with respect to binding other proteins to the active site. Preferably, the protein comprising a free cysteine ​​thiol group is obtained by cleaving a disulfide bond in the protein that is not required to maintain the integrity of the protein binding site, i.e. the activity of the protein to bind other proteins. Preferably, disulfides are reduced using tris(2-carboxyethylphosphine) hydrochloride (TCEP.HCl), which can be used at a pH between 1.5 and 9.0, depending on the stability of the protein to be reduced at that pH. Typical pHs for reduction are pH 3 to pH 8, using non-phosphate buffers, e.g., TRIS, HEPES, borate. One advantage of TCEP is that it does not contain thiol groups and therefore does not require removal of the free sulfhydryls of the protein before reacting with the epoxide groups on the nanofibers. Additional reducing agents include dithiothreitol (DTT), mercaptoethanol (ME), 2-mercaptoethylamine hydrochloride (2-MEA.HCl), all typically utilized near neutral pH. All three of these reagents contain free thiol groups, which can be removed from the protein by filtration before reacting the protein with the nanofibers to reduce competing reactions during protein conjugation. Cysteine-cysteine ​​disulfide bonds are often found in proteins as a way to maintain protein structure, and cleavage of these disulfide bonds can result in denaturation of the protein. Other structural features, such as beta sheets, helical bundles, and hairpin structures, can maintain protein conformation without the use of disulfide bonds. Preferably, proteins useful for affinity binding of other proteins or useful biological therapeutic molecules are recombinantly produced or isolated from natural sources.Preferably, the protein is recombinantly produced to contain disulfide bonds that are not involved in the conformational stability of the resulting protein; preferred proteins of this type include Protein A, Protein A / G, and Protein G. Other preferred proteins include antibodies (monoclonal and polyclonal), recognition fragments F(ab') and F(ab')2, which can be generated recombinantly or after enzymatic treatment to cleave the fragments from intact antibodies (Rosenstein et.al., Curr Protoc Mol Biol. 2020 Jun; 131(1):e119.doi:10.1002 / cpmb.119). Preferably, the disulfide bond reduced in F(ab')2 is distal to the binding site of the protein and can be cleaved to form individual fragments without losing the ability to bind other proteins, presumably because the disulfide bonds that help maintain the conformation of the protein occur within β-secondary structures, such as β-sheets, which maintain the conformation of the protein and protect these disulfides from reduction. Preferably, the protein is present in the aqueous solution at a concentration of 5 to 50 mM. Preferably, the pH of the solution is 8 to 9.5, preferably 8.5 to 9.3, preferably 8.7 to 9.1, and the molecular weight of the protein is 150,000 daltons or less, preferably 100,000 daltons or less, preferably 75,000 daltons or less.

[0015] Preferably, a dielectric barrier discharge atmospheric pressure plasma process is used to attach the functionalized monomer and protein injected as a liquid aerosol to the nanofiber substrate. The dielectric barrier discharge plasma process is preferably a homogeneous glow discharge process. Homogeneous glow discharge plasma processes are known in the art for generating spatially uniform cold electrons from an injected gas at atmospheric pressure. The ions collide with the injected monomer to generate ionized species that can self-polymerize in the aerosol prior to substrate deposition. Preferred gases suitable for plasma generation include carbon dioxide, nitrogen, argon, and / or helium. The flow of gas in plasma form and the injected monomer aerosol passes through a nozzle with a defined cross-sectional area. Preferably, for treating nonwoven roll goods, the nozzle is rectangular in shape with a width greater than the interelectrode gap and the width of the nonwoven. The interelectrode gap is preferably 0.5-10 mm, preferably 0.8-2 mm. The cross-sectional area of ​​the nozzle used in the following examples is 5 cm with a nozzle width of 40 cm. 2 Preferably, the gas flow rate is 2 to 150 slm / cm. 2 The standard conditions for the gas volume are a temperature of 0°C and a pressure of 1 atm (101 kPa), and are preferably in the range of 60 to 100 slm / cm. 2 The gas flow rate through the plasma head depends on the plasma head size and the width of the substrate to be coated with the monomer, as well as the ambient temperature and pressure of the gas. The injected monomer flow rate depends on the amount of monomer to be bonded per area of ​​the substrate. A high injection rate of the monomer may result in self-polymerization before deposition on the substrate. Preferably, the injection rate of the aerosolized monomer is less than 0.2 slm / cm. 2 ~5slm / cm 2The dilution of the monomer may be accomplished by one or both of the following means: liquid solution mixing, dissolving or suspending the solid monomer in water or a suitable solvent, and introducing a larger gas flow into the liquid monomer pure compound, suspension, or solvent mixture. The preferred dilution ratio (solvent or carrier to monomer) is in the range of 2:1 to 50:1, preferably 3:1 to 20:1. Preferably, the coated electrode, supplied with AC power, generates a plasma through a narrow gap at atmospheric pressure of 0.9 to 1.1 atm (91 to 111 kPa). Preferably, the plasma source voltage is in the range of 1 to 100 kV, preferably in the range of 5 to 30 kV. Preferably, the supplied power for the initial activation and reaction with the monomer is in the range of 2 to 300 W / cm. 2 , preferably 20 to 200 W / cm 2 , preferably 30 to 160 W / cm 2 Preferably, the power supplied in the presence of protein is in the range of 1 to 100 W / cm 2 , preferably 2 to 40 W / cm 2 , preferably 3 to 20 W / cm 2 Preferably, the distance between the substrate and the plasma head is 1-10 mm, preferably 2-5 mm. Preferably, the substrate is pretreated in a monomer-free atmospheric pressure plasma process using carbon dioxide, nitrogen, argon, and / or helium. EXAMPLES

[0016] Nonwoven webs from non-carbohydrate based polymers, used as examples and shown in Table I, were prepared by an electrospinning process similar to that described in https: / / pubs.acs.org / doi / 10.1021 / acs.chemrev.8b00593. Similar non-carbohydrate webs can be produced by an electroblowing process, as described in U.S. Pat. No. 7,618,579. These nonwoven webs may then be consolidated as described in U.S. Pat. No. 8,697,587 B2. The spinning and consolidation process was adjusted so that the porosity of the resulting web ranged between 35% and 95% and the average through-pore size was between 0.1 μm and 5 μm.

[0017] [Table 1]

[0018] Exemplary nonwoven substrates were pretreated with plasma and then treated by a plasma coating process (see, e.g., U.S. Pat. Nos. 8,663,751, 9,890,260, and 9,938,388) using functionalizing agents ("agents") and process conditions in which various amounts of agent were injected into the plasma and applied to the substrate. The plasma process conditions for epoxide or methacrylic deposition onto the exemplary nonwoven are shown in Table II as vinyl-functionalized Example Nos. 1 and 2. Each nanofiber nonwoven web was subjected to an activation pass through the plasma treatment device, and the top and bottom surfaces of the webs were treated with 80 slm / cm 2 and 8 slm / cm 2 and 300W / m 2 The activated nanofiber web is exposed to a plasma of CO2 and N2 at a power level of 80 slm / cm 2 The substrate was passed through a N2 plasma with a flow rate of 1000 s. The distance between the electrode and the substrate was 2 mm.

[0019] [Table 2]

[0020] Functionalization Example 1 Hydrolyzed recombinant Protein A was thawed and dissolved in a nebulizer vial containing deionized water at a concentration of 11 mg Protein A per mL of solution. No reduction reaction was performed before the solution was aerosolized and co-injected with GMA into the argon plasma. The protein plasma was directed at the moving substrate, vinyl-functionalized Example 1 in Table II. Plasma process conditions were 60 slm / cm. 2 A 3:1 blend of Ar and N gas at 1000 nm of Ar, 2 mm substrate-to-electrode distance, and 40 W / cm 2 An atmospheric pressure plasma process was used with an applied power to the plasma of 1000 slm / cm and co-injection of a 50:50 volume ratio of Protein A solution and GMA. The solutions were injected at 2 slm / cm. 2 The resulting protein-functionalized nanofiber substrate with Protein A was tested as is for saturation binding capacity.

[0021] Functionalization Example 2 Hydrolyzed recombinant protein A was thawed and dissolved in a vial containing deionized water at a concentration of 11 mg protein A per mL of solution. The solution was aerosolized and subjected to a reduction reaction before being co-injected with GMA into an argon plasma. Reduction of the disulfide bonds in the protein A dimer was performed using TCEP-HCl (tris(2-carboxyethyl)phosphine hydrochloride) in aqueous solution at concentrations of 5–50 mM, pH 6–8 [see Thermo Fisher Application Notes, https: / / www.thermofisher.com / us / en / home / references / molecular-probes-the-handbook / thiol-reactive-probes / introduction-to-thiol-modification-and-detection.html]. Excess TCEP was filtered from the solution using a Sephadex column, followed by elution with deionized water. The pH of the filtered solution was adjusted using 3 M ammonium carbonate (AC) and 0.5 mL of AC was added to each 1.5 mL of filtered reduced Protein A solution until the pH was 9.5. The pH adjusted protein plasma was directed onto the transfer substrate, vinyl-functionalized Example 1 of Table II. The plasma process conditions were 60 slm / cm. 2 A 3:1 blend of Ar and N gas at 1000 nm of Ar, 2 mm substrate-to-electrode distance, and 40 W / cm 2 An atmospheric pressure plasma process was used with an applied power to the plasma of 1000 slm / cm and co-injection of a 50:50 volume ratio of Protein A solution and GMA. The solutions were injected at 2 slm / cm. 2 The resulting protein-functionalized nanofiber substrate with Protein A was tested as is for saturation binding capacity.

[0022] Functionalization Example 3 A 20 mg / mL solution of recombinant Protein A in deionized water was prepared in a 50 mL vial. 0.5 M TCEP was added to reduce disulfide bonds and incubated at room temperature for 10 min. The reaction mixture was filtered through a Sephadex column and 103 After reacting with an equivalent amount of GMA, it was treated with 1 M ammonium formate. The resulting GMA-modified recombinant Protein A solution was filtered again and then purified by co-aerosolization with HEMA at 40 W / cm under the same conditions as in Functionalization Example 2 for the vinyl-functionalization Example 2. 2 The nanofiber substrates were then injected into an Ar / N atmospheric pressure plasma at 1000 rpm. The resulting protein-functionalized nanofiber substrates with Protein A were directly tested for saturation binding capacity.

[0023] Functionalization Example 4 The same GMA modification solution prepared in Functionalization Example 3 is introduced into the vinyl-functionalized Example 2 in the same plasma process as Functionalization Example 2, but the aerosol dilution is increased to 7: 1. The resulting protein-functionalized nanofiber substrate with Protein A was directly tested for saturation binding capacity.

[0024] Functionalization Example 5 Vinyl-functionalized Example 1 of Table II is conjugated in solution to reactive cysteines on recombinant Protein A. The reaction involves first reducing the disulfide bonds in Protein A dimers using TCEP-HCl (tris(2-carboxyethyl)phosphine hydrochloride) in aqueous solution at a concentration of 5-50 mM and pH 6-8 [see Thermo Fisher application notes, https: / / www.thermofisher.com / us / en / home / references / molecular-probes-the-handbook / thiol-reactive-probes / introduction-to-thiol-modification-and-detection.html]. Protein A with free reactive thiols is then reacted with the soaked epoxy-activated nanofiber mat in the presence of a salting-out buffer, e.g., sodium sulfate, to increase the coating of Protein A on the surface of the fibers, thereby increasing the local concentration of Protein A at the surface of the fibers and increasing the amount of Protein A conjugated to the nanofiber mat [see Thermo Fisher application notes, https: / / www.thermofisher.com].

[0025] Comparative Example 1 Vinyl-functionalized Example 2 is tested neat, ie, without conjugation with plasma or solution-based Protein A, for saturation binding capacity. The saturation binding capacity SBC can be measured by placing a 2.5 cm diameter disk of membrane in a Swinnex filter holder and using AKTA Pure™ to elute 10 mL of human IgG (0.2 mg / mL) in PBS buffer (pH 7.4) through the membrane at 0.5 ml / min. The filter is then washed with about 10 bed volumes of PBS buffer, and the human IgG is then eluted from the membrane with 5 bed volumes of buffer (e.g., 0.1 M glycine at pH 3), quickly neutralized to about pH 7 to avoid denaturation, and the concentration is measured spectrophotometrically using the following formula or by integration of the elution curve and compared to a calibration curve (e.g., Hahn et.al. Journal of Chromatography A. 2005, 1093, 98).

[0026] Protein concentration Protein concentration (mg / ml): absorbance x dilution x (molecular weight / molar extinction coefficient) The results of saturation binding capacity measurements of the functionalized nanofiber surfaces are shown in Table III and demonstrate the improved binding capacity of all structures when exposed to Protein A via either atmospheric plasma or solution-based processes.

[0027] [Table 3]

[0028] Functionalization Example 6 The vinyl-functionalized nanoweb of Example 1 was conjugated with Protein A, supplied by Repligen Corporation, Waltham, Massachusetts. This type of Protein A binds to the vinyl-functionalized nanoweb via amine groups. Successful conjugation was demonstrated by binding of IgG to the Protein A-functionalized nanoweb, as demonstrated by the results in Table IV. Capacity testing was performed as described above in the paragraph following Comparative Example 1.

[0029] [Table 4]

Claims

1. 1. A method for functionalizing a nanoweb having an average through pore size of 0.1 to 5 μm and a porosity of 40 to 90 volume percent to produce a functionalized nanoweb, said method comprising: a) exposing the nanoweb and a vinyl monomer to an atmospheric plasma to produce a coated nanoweb; b) exposing the coated nanoweb and an aerosol containing molecules capable of forming covalent bonds to an atmospheric pressure plasma; A method comprising:

2. The method of claim 1 , wherein the nanoweb is a non-carbohydrate polymer.

3. 3. The method of claim 1 or 2, wherein the nanoweb comprises PVDF, polyamide, polyethersulfone, polyethylene, polypropylene, polyester, or polyimide.

4. The method of any one of claims 1 to 3, wherein the vinyl monomer comprises at least one epoxy group.

5. The method of any one of claims 1 to 4, wherein the molecules capable of forming a covalent bond comprise molecules containing at least one of a hydroxyl, amine, or thiol group.

6. The method of any one of claims 1 to 5, wherein the aerosol comprises a non-volatile buffer.

7. The method of any of claims 1 to 6, wherein the vinyl monomer comprises an ester or ether of (i) an epoxy alcohol, or (ii) an acetylenic alcohol.

8. The method according to any one of claims 1 to 7, wherein the molecule is capable of binding a protein to an active site.

9. The method of any one of claims 1 to 8, wherein the molecule comprises at least one protein.

10. The method of claim 9 , wherein the protein is capable of binding other proteins to an active site.

11. 1. A method for functionalizing a nanoweb having an average through pore size of 0.1 to 5 μm and a porosity of 40 to 90 volume percent to produce a functionalized nanoweb, said method comprising: a) exposing the nanoweb and a vinyl monomer to an atmospheric plasma to produce a coated nanoweb; b) exposing the coated nanoweb to a molecule capable of forming a covalent bond; A method comprising:

12. The method of claim 11 , wherein the nanoweb is a non-carbohydrate polymer.

13. 13. The method of claim 11 or 12, wherein the nanoweb comprises PVDF, polyamide, polyethersulfone, polyethylene, polypropylene, polyester, or polyimide.

14. The method of any of claims 11 to 13, wherein the vinyl monomer comprises at least one epoxy group.

15. The method of any of claims 11 to 14, wherein the molecules capable of forming a covalent bond comprise molecules containing at least one of a hydroxyl, amine, or thiol group.

16. The method of any of claims 11 to 15, wherein the vinyl monomer comprises an ester or ether of (i) an epoxy alcohol, or (ii) an acetylenic alcohol.

17. 1. A method for functionalizing a nanoweb having an average through-pore size of 0.1 to 5 μm and a porosity of 40 to 90% by volume to produce a functionalized nanoweb comprising a protein, the method comprising: a) exposing the nanoweb, a first vinyl monomer, and a second vinyl monomer to an atmospheric pressure plasma to produce a coated nanoweb; b) exposing the coated nanoweb to a molecule capable of forming a covalent bond; A method comprising:

18. The method of claim 17 , wherein the nanoweb is a non-carbohydrate polymer.

19. 19. The method of claim 17 or 18, wherein the nanoweb comprises PVDF, polyamide, polyethersulfone, polyethylene, polypropylene, polyester, or polyimide.

20. The method of any of claims 17 to 19, wherein the first vinyl monomer comprises at least one epoxy group.

21. The method of any of claims 17 to 20, further comprising a second vinyl monomer comprising at least one hydrophilic group.

22. The method of any of claims 17 to 21, wherein the molecules capable of forming a covalent bond comprise molecules containing at least one of a hydroxyl, amine, or thiol group.

23. The method of any one of claims 17 to 22, wherein the aerosol comprises a non-volatile buffer.

24. The method of any of claims 17 to 23, wherein the first vinyl monomer comprises an ester or ether of (i) an epoxy alcohol, or (ii) an acetylenic alcohol.

25. The method of any one of claims 17 to 24, wherein the molecule comprises at least one protein.

26. 26. The method of claim 25, wherein the protein is capable of binding other proteins to an active site.